Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00130169 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00130169 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 30 participants.
The verdict
NCT00130169, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of E7974 administered on Days 1 and 15 of a 28-day cycle in subjects with solid malignancies that have progressed following effective therapy or for which no effective therapy exists.
Interventions
- DRUG E7974
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-01 |
| Est. Completion | 2009-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00130169
The ClinicalTrials.gov registry entry for NCT00130169 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which E7974 is the first listed.
NCT00130169 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00130169 about?
NCT00130169 is a clinical study titled "A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies". The purpose of this study is to determine the maximum tolerated dose (MTD) of E7974 administered on Days 1 and 15 of a 28-day cycle in subjects with solid malignancies that have progressed following effective therapy or for which no effective therapy exists.
What is the current status of trial NCT00130169?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2006-01. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00130169?
The interventions under investigation include: E7974 (DRUG).
Who is sponsoring clinical trial NCT00130169?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.